Position in LYEL
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$146,836
-$298,636 QoQ
Shares Held
10,451
-52.9% QoQ
Ownership
0.043%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#54
of 87 holders
Holding Since
Dec 2021
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. LYEL ranks #98 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in LYEL
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $146,836 | 10,451 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $445,472 | 22,207 | Shares | Sole | 2026-05-13 | |
| 2025-06-30 | $258,393 | 29,230 | Shares | Sole | 2025-08-13 | |
| 2022-12-31 | $203,970 | 58,781 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,620,025 | 221,013 | Shares | Sole | 2022-11-14 | |
| 2022-03-31 | $812,731 | 160,937 | Shares | Sole | 2022-05-27 | |
| 2021-12-31 | $92,872 | 11,999 | Shares | Sole | 2022-05-27 | |
| No filing history on record for this holder in this stock. | ||||||